Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., along with its wholly-owned subsidiaries, is a global leader in insulin delivery and diabetes technology. The company specializes in designing, developing, and selling advanced solutions to ease the burden of diabetes management. Tandem serves nearly 500,000 people living with diabetes in more than 25 countries worldwide. Its strategy focuses on providing flexible and diverse intelligent insulin delivery systems through a portfolio of market-leading pumps, applications, and insights. Key pump platforms include t:slim X2 and Tandem Mobi (Mobi), both equipped with Control-IQ+ advanced hybrid closed-loop technology. Diabetes is a chronic, life-threatening disease with no known cure, typically classified as type 1 or type 2. Type 1 diabetes involves the body's near-complete inability to produce insulin, often diagnosed in childhood or adolescence, requiring intensive insulin therapy for survival. Type 2 diabetes involves the body's inability to properly use or produce enough insulin, a progressive condition where advanced stages often require intensive insulin therapy. The Center for Disease Control and Prevention estimates Type 2 accounts for 90-95% of diagnosed adult diabetes in the United States. Tandem's addressable market includes people with type 1 diabetes and, as of 2025, expanded to include people with type 2 diabetes who require intensive insulin therapy, referred to as people with insulin-dependent diabetes. In the geographies served, an estimated 5 million people live with type 1 diabetes, with approximately 2 million in the United States. Additionally, an estimated 2.5 million people in the United States live with type 2 diabetes and require intensive insulin therapy.